anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Intracerebral hemorrhage (ICH) is one of the major causes of death and disability, and hypertensive ICH (HICH) is the most common type of ICH. Currently, the outcomes of HICH patients remain poor after treatment, and early prognosis prediction of HICH is important. However, there are limited effective clinical treatments and biomarkers for HICH patients. Although circRNA has been widely studied in diseases, the role of plasma exosomal circRNAs in HICH remains unknown. The present study was conducted to investigate the characteristics and function of plasma exosomal circRNAs in six HICH patients using circRNA microarray and bioinformatics analysis. The results showed that there were 499 differentially expressed exosomal circRNAs between the HICH patients and control subjects. According to GO annotation and KEGG pathway analyses, the targets regulated by differentially expressed exosomal circRNAs were tightly related to the development of HICH via nerve/neuronal growth, neuroinflammation and endothelial homeostasis. And the differentially expressed exosomal circRNAs could mainly bind to four RNA-binding proteins (EIF4A3, FMRP, AGO2 and HUR). Moreover, of differentially expressed exosomal circRNAs, hsa_circ_00054843, hsa_circ_0010493 and hsa_circ_00090516 were significantly associated with bleeding volume and Glasgow Coma Scale score of the subjects. Our findings firstly revealed that the plasma exosomal circRNAs are significantly involved in the progression of HICH, and could be potent biomarkers for HICH. This provides the basis for further research to pinpoint the best biomarkers and illustrate the mechanism of exosomal circRNAs in HICH.
ETHNOPHARMACOLOGICAL RELEVANCE: In TCM opinion, most of pneumonia is related to "lung heat". Sophora davidii (Franch.) Skeels flower was first documented in "Guizhou Herbal Medicine", and was recorded as having functions of clearing heat, detoxifying, and cooling blood. It can be used to treat lung heat cough.
AIM OF THE STUDY: To investigate main mechanisms of Sophora davidii flower extract (SDFE) in Treating LPS-induced acute Pneumonia.
MATERIALS AND METHODS: Acute pneumonia models on BEAS-2B cells and rats were established using LPS. The rat model was used to verified the protective effects of SDFE through HE staining, lung tissue W/D ratio assay, white blood cell count analysis, and ammonia-induced coughing test. Network pharmacology was applied to predict the active compounds, core targets and main pathways of SDFE in treating acute pneumonia. Western Blot and ELISA kits were employed to validate representative proteins in selected pathway in vivo and in vitro.
RESULTS: HE staining, lung tissue W/D ratio assay, white blood cell count analysis, and ammonia-induced coughing test showed SDFE could improve pathological features (leukocyte infiltration, pulmonary edema, lung injury and cough). Network pharmacology indicated MAPK/NF-κB pathway was the most relevant pathway. SDFE could significantly inhibit the expression of Fos and Jun, and the phosphorylation levels of p38, ERK, JNK, NF-κB and IκB. It also down-regulated the expression of pro-inflammatory factors (TNF-α, IL-6 and IL-1β).
CONCLUSIONS: SDFE can exert protective effects against acute pneumonia through the MAPK/NF-κB signaling pathway.
Systems and method for displaying a patient specific report are provided. The report includes a determination of an allele status for genomic loci. Each respective loci associates with an efficacy of a treatment for at least one neuropsychiatric disorder and one or more treatments of the at least one disorder. A respective graphical chart displays for each corresponding disorder including a respective first axis, a respective second axis, and respective data plots. The respective first axis segments into bins. Each respective bin associates with a respective independent first subset of loci and represents a respective treatment class. The second respective axis is associated with a characteristic of an efficacy of a treatment for the corresponding disorder. Each respective data plot represents a corresponding treatment, is within the corresponding bin, and independently located on the first respective axis based on an allele status for the respective independent first subset of loci.
On volunteers initial visit to the lab, they will be screened to assess their inclusion using the inclusion and exclusion criteria. Those who qualify for the study will be informed of the detailed procedures of the study. If they still decide to participate, they will be asked to read and sign the informed consent form. They will be asked to avoid taking NSAIDS during the course of the study. Participants will also be asked to refrain from the consumption of flavonoid-rich foods, drinks and supplements for 7 days prior to the test day. During the second visit (test day), baseline data such as body composition, anthropometrical variables, inflammatory markers (creatine kinase, TNF-α, IL-1 and IL-6), perceived muscle soreness and recover, and the quadriceps muscle functioning will be measured. The test will be done in the morning between 8:00 and 12:00 noon. To standardize the metabolic state of the participant during the testing sessions they will not be required to eat for at least two hours before testing. Moreover, participants will be required not to take caffeinated drinks and alcohol at least 12 hours before testing and not do any vigorous activities that have a rating of perceived exertion (RPE) more than (\>) 12 on the Borg scale or any unusual exercise at least 24 hours before testing.

Participants will perform an 8 min warm-up of brisk walking on a treadmill (4-7 kph). They will then be subjected to the BIODEX exercise protocol. The protocol is composed of two exercise bouts (A and B), each of which comprises of 15 series of 12 maximum intermittent knee extensions conducted using the right leg on an isokinetic dynamometer with a 60 min break in between. During the 60 min break, the participants will cycle at 100 W on a bicycle ergometer (Monark) for 15 min in between bouts A and B, and then they rested in a semi-supine position for the next 45 min until bout B began. After completion of the exercise protocol, each participant will be asked to step down a total of four times from a bench 30.45 cm (1 ft.) high, alternating the leading leg between attempts to have each leg lead twice to assess the perceived muscle soreness using a 100-point visual analogue scale (VAS).

Participants will then be randomised into two (2) groups; the Aspalathus linearis group (AG) and the control group (CG). Participants will be asked to return after 24, 48 and 72 hours of the exercise. During each visit, the baseline measurements, perceived muscle soreness and muscle recovery will be repeated.
AIMS: Understanding of the tissue cooling properties of cryoballoon ablation during pulmonary vein (PV) isolation is lacking. The purpose of this study was to delineate the depth of the tissue cooling effect during cryoballoon freezing at the pulmonary venous ostium.
METHODS AND RESULTS: A left atrial-PV model was constructed using a three-dimensional printer with data from a patient to which porcine thigh muscle of various thicknesses could be affixed. The model was placed in a 37°C water tank with a PV water flow at a rate that mimicked biological blood flow. Cryofreezing at the PV ostium was performed five times each for sliced porcine thigh muscle of 2, 4, and 6 mm thickness, and sliced muscle cooling on the side opposite the balloon was monitored. The cooling effect was assessed using the average temperature of 12 evenly distributed thermocouples covering the roof region of the left superior PV. Tissue cooling effects were in the order of the 2, 4, and 6 mm thicknesses, with an average temperature of -41.4 ± 4.2°C for 2 mm, -33.0 ± 4.0°C for 4 mm, and 8.0 ± 8.7°C for 6 mm at 180 s (P for trend <0.0001). In addition, tissue temperature drops were steeper in thin muscle (maximum temperature drop per 5 s: 5.2 ± 0.9°C, 3.9 ± 0.7°C, and 1.3 ± 0.7°C, P for trend <0.0001).
CONCLUSION: The cooling effect of cryoballoon freezing is weaker in the deeper layers. Cryoballoon ablation should be performed with consideration to myocardial thickness.
The present invention relates to a composition comprising sulfated saccharide fucoidan having a molecular weight of less than 3kDa as an active ingredient. The sulfated saccharide fucoidan of less than 3kDa, which is an active ingredient used in the composition of the present invention, has excellent effect of improving skin conditions when compared with other fucoidan fractions. Here, the improvement of the skin conditions includes a wrinkle improvement effect, an anti-oxidant effect, an anti-inflammatory effect, and an anti-aging effect. Fucodian exhibits excellent wrinkle improvement effect through molecular mechanisms such as the promotion of collagen synthesis and the protection of fibroblasts, and also has an effect of inhibiting collagenase activity. Additionally, fucoidan has an effect of inhibiting an inflammatory response, and an anti-oxidant effect through a mechanism of protecting from oxidative damage due to activated oxygen. Also, the composition of the present invention can be safely applied to a cosmetic agent and pharmaceutical and food compositions without cytotoxicity and side effects to the skin.
In the controlled clinical trials, mild pain (including transient burning and stinging) was reported by about 30% of patients in both the active and placebo arms; treatment was discontinued in 2 of these patients. Local pruritus occurred in 4% of these patients. In all studies, there was no significant difference between the drug and placebo group in the rate or type of reported adverse reactions nor were there any differences in abnormal clinical laboratory findings.

Observed During Clinical Practice: Based on clinical practice experience in patients treated with Acyclovir Ointment in the U.S., spontaneously reported adverse events are uncommon. Data are insufficient to support an estimate of their incidence or to establish causation. These events may also occur as part of the underlying disease process. Voluntary reports of adverse events that have been received since market introduction include:

General: Edema and/or pain at the application site.

Skin: Pruritus, rash.

To report SUSPECTED ADVERSE REACTIONS, contact Camber Pharmaceuticals, Inc. at 1-866-495-1995 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Cancer-related anorexia-cachexia (CRAC) comprises one of the most common syndromes of advanced cancer patients. The prevalence of CRAC increases from 50% to 80% before death. CRAC is associated not only with impaired quality of life in patients and family members but also with shorter survival. The management of CRAC is a great challenge in clinical practice. There are no definite practice guidelines yet for the prevention and treatment of CRAC. A multimodal strategy is the most effective way to treat anorexia-cachexia. Numerous medications have been suggested and used in clinical trials, while others are still being studied on experimental animals. These medications include branched-chain amino acids, eicosapentaenoic acid, thalidomide, cytokine inhibitors, steroids, antiserotoninergic medications, and appetite stimulants. The benefits of supportive care interventions and the advancement of exciting new pharmacological medicines for anorexia-cachexia are becoming more widely recognized. Health care professionals need to be aware of the psychosocial and biological effects of anorexia-cachexia, even though knowledge of the underlying molecular causes of the disorder has advanced significantly.
PURPOSE:To obtain the subject composition having improved solubility in aqueous solution and high absorbability through digestive tracts by using an amorphous material containing a specific compound useful as a hypotensor and a pH-dependent methacrylic copolymer as an active component. CONSTITUTION:The objective composition contains, as an active component, an amorphous material containing methyl 3-phenyl-2(E)-propenyl 1,4-dihydro-2,6- dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate useful as a hypotensor and a pH-dependent methacrylic copolymer. The pH-dependent methacrylic copolymer is e.g. a trimethylammonium salt of a copolymer of acrylic acid and methacrylic acid, more concretely, Eudragit L, etc. The amount of the copolymer is preferably 30-1,000 pts.wt. per 100 pts. wt. of the hypotensive compound.
A neural network embodiment comprises an input layer, an output layer and a filter layer. Each unit of the filter layer receives a filter layer input from a single preceding unit via a respective filter layer input connection. Each filter layer input connection is coupled to a different single preceding unit. The filter layer incentivizes the neural network to learn to produce a target output from the output layer for a given input to the input layer while simultaneously learning weights for each filter layer input connection. The weights learned cause the filter layer to reduce a number of filter layer units that pass respective filter layer inputs as non-zero values. When applied as an initial internal layer between an input layer and an output layer, the filter layer incentivizes the neural network to learn which neural network input features to discard to produce the target output.
Participants will receive abiraterone acetate (AA) along with prednisone on Day 1, Treatment Cycle 1 up to Day 7, Treatment Cycle 1; followed by combined intake of AAP + JNJ-56021927 from Day 8, Treatment Cycle 1 up to the end of treatment (EoT) visit (ie, up to approximately 18 months). On Days 7 and 36, participants will receive AA and prednisone together. On Day 8, Treatment Cycle 2 participants will receive JNJ-56021927, 1 hour after intake of AAP. Treatment cycles will be of 28 days.
BACKGROUND: There is insufficient attention to hypogonadism in Chinese males with type 2 diabetes mellitus (T2DM). We evaluated the relationship between Combined obesity- and lipid-related indices [Visceral Adiposity Index (VAI), Chinese Visceral Adiposity Index (CVAI), Triglyceride Glucose Index (TyG) and Lipid Accumulation Product (LAP)] with total testosterone (TT) and analyzed the predictive capability of the respective cut-off values.
METHODS: We recruited 958 hospitalized male patients with T2DM at the Affiliated Hospital of Qingdao University, collected baseline data and four calculated indices, and obtained their dominance ratio (OR) and corresponding 95% confidence intervals (CI) with TT by multivariate logistic regression. Receiver operating characteristic (ROC) curves were then used to determine cutoff values in predicting hypogonadism (TT< 12 nmol/L), and we also analyzed the combinations between the different indices.
RESULTS: VAI, CVAI, TyG, and LAP all have satisfactory predictive capabilities. The test capability (sensitivity and specificity) of all four indices was better or not worse than that of body mass index (BMI), homeostasis model assessment of insulin resistance (HOMA-IR) and waist circumference (WC). All four indices were effective predictors of hypogonadism at their respective cutoff values (VAI ≥ 2.284, CVAI ≥ 145.779, TyG ≥ 4.308, and LAP ≥ 59.850). Of these, LAP had the largest area under the curve (AUC, AUC = 0.852, Std. Error = 0.014, 95% CI = 0.818-0.873). However, the predictive capability of the combined indices was not significantly improved over the individual indices.
CONCLUSIONS: VAI, CVAI, TyG, and LAP are sensitive indices for predicting hypogonadism in Chinese male patients with T2DM. Considering the need for concise and accurate indices in clinical practice, we suggest LAP as a commonly used index.
NicoDerm® CQ® patch (21 mg) with committedquitters.com. The NicoDerm patch transdermally administers 21 mg of nicotine per day. The NicoDerm patch is applied each morning of the treatment period after waking and worn for approximately 24 hours.
The present invention relates to a bivalent peptide vaccine, it's preparation methods and applications. The said vaccine is obtained by biological engineering technology, and comprising a peptide encoded by 2 n-1 tandem nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 2., where n is the integer of 1-5. The. vaccine provided by the present invention is safe and has high immunoreactivity. It's suitable for mass manufacturing and can prevent or treat foot-and-mouth disease (FMD) effectively. It can also be used to distinguish between infected and vaccinated animals.
Lithium derivatives of pyrroloquinoline quinone and preparation method thereof are disclosed. In said method, lithium derivatives of pyrroloquinoline quinone are obtained by an acid-base neutralization reaction in a basic solvent with pyrroloquinoline quinine (PQQ) as a starting material. Lithium ion is brought in the molecular structure of pyrroloquinoline quinone to form said lithium derivatives of pyrroloquinoline quinone. The reaction condition of said method is mild, the product is easy to be purified, the preparation procedure is simple, and the yield is more than 80 %. Said lithium derivatives of pyrroloquinoline quinone possess GSK-3 inhibiting activity and possess the functions such as reducing the formation of age pigment in the brain of a transgenic mouse and reducing the phosphorylation of tau proteins. Said lithium derivatives of pyrroloquinoline quinone may be used in the manufacture of medicaments for preventing and treating senile dementia, senility or Parkinson's disease.
This prospective anatomical study aimed to establish an ultrasound-guided technique to the quadratus lumborum (QL) plane in sheep cadavers. Thirteen cadavers, weighing less than 117 kg, were included. In phase 1, one cadaver underwent dissection and two cadavers underwent 3D computed tomographic reconstruction for anatomical evaluation of the thoracolumbar region. In phase 2, two cadavers were used to compare two ultrasound techniques to the QL plane: lateral to the QL muscle with a transversal approach (LQL) and transmuscular between QL and psoas muscles with a longitudinal approach (TQL). For LQL, the reference was the first lumbar transverse process, whereas for TQL, it was the intertransverse region between the first and second lumbar vertebrae. The needle was advanced in-plane towards the specific target for each technique and a total of four injections were performed using 0.4 ml kg-1 of a dye-lidocaine solution. In phase 3, 10 cadavers received bilateral LQL injections (n = 20). All cadavers were then dissected to evaluate spread of dye. In phase 2, following LQL injections, no dye was observed in undesired locations; however, the dye was noted in the retroperitoneal space (1/2) after TQL injections. In phase 3, the 13th thoracic, first, second, third lumbar nerves, and sympathetic trunk segments were stained in 80%, 95%, 100%, 45% and 35% of the injections, respectively. In conclusion, the LQL technique was feasible, allowing staining of the spinal nerves innervating the cranial abdomen in sheep cadavers. Further studies in live animals are warranted.
<P>PROBLEM TO BE SOLVED: To provide an exocrine functional disorder-improving agent effective for the prevention and improvement of dry eye or dry mouth, and having high safety.  <P>SOLUTION: This exocrine functional disorder-improving agent is characterized by blending betel nut. The preventing and improving agent of the dry mouth is characterized by blending the betel nut. The preventing and improving agent of the dry eye is characterized by blending the betel nut. The exocrine functional disorder-improving agent is useful as the drug, quasi drug or food for preventing or improving the dry eye or dry mouth.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention discloses a reagent for diagnosing oral cavity disease. Bengal red is selected as a coloring agent. The coloring agent and the DNA polymerase of a tumour cell have affinity. The coloring of the coloring agent has a specificity to the diagnosis of oral cavity cancer. The coloring dark and light degree of the coloring agent can identify oral cavity cancer and damage before the oral cavity cancer. A prepared Bengal red reagent for diagnosing oral cavity cancer is composed of the following raw materials: sodium bicarbonate, formaldehyde, or ethanol, Bengal red and distilled water which are prepared according to a certain proportion. The present invention has the advantages of simple technology, reasonable compatibility, safety, innocuity and simple and convenient operation. The inspection and diagnosis rate and a disease inspection positive rate of disease are enhanced. The reagent can be used for the self recognition of the disease state of a patient, and is helpful to the clinic early diagnosis of the oral cavity cancer.
This in an open-label, multicenter, multiple-dose investigation of 2 doses of leuprolide acetate 22.5 mg administered with a 3-month interval to patients with histologically proven carcinoma of prostate who might benefit from medical androgen deprivation therapy. A total of up to 160 male patients will receive their first single intramuscular injection of leuprolide acetate 22.5 mg on Day 0 (after baseline assessment) and then after 3 months (Day 84). The study duration will be 6 months. Thirty(30) patients will be screened per protocol and enrolled at selected centers to form the PK cohort. The PK/PD analysis will be performed using plasma specimens from the first 20 of 30 patients enrolled in the study (and included in the PK/PD cohort). Patients not belonging to the PK cohort will be screened and enrolled per protocol and will follow the same study schedule as those enrolled in the PK portion of the study, except they will provide only sparse PK sampling.
The subjects will be delivered five pre-made ready meals per day throughout the period (5 weeks). These will contain age- and gender-specific recommended amount of calories but the amount of carbohydrates would be limited to provide only 15% (+/- 5%) of the recommended energy a day.
This study, conducted over 4 years in Baghdad, Iraq, aimed to determine the importance of ureteric jet assessment in medical expulsive therapy (MET) for distal ureteral stones. A total of 156 patients with distal ureteral stones (≤ 10 mm) participated, and their ureteric jets were observed using a color Doppler scanner before and after 2 weeks of MET. The main focus was the success rate of stone expulsion. Our results showed that 50% of patients had detectable ureteric jets after 2 weeks of MET, and 21.8% experienced successful stone expulsion. After 4 weeks, 23.7% achieved stone expulsion, while 54.5% still had remaining stones. Patients who had a positive baseline ureteric jet were significantly more likely to successfully expel their stones. This study highlights the importance of monitoring ureteric jet movement in MET for distal ureteral stones.
The invention discloses application of isosteviol in preparation of a medicament for treating autoimmune hepatitis. Compared with the prior art, the invention discovers that isosteviol improves mouse immune liver injury induced by concanavalin A (concanavalin A). Isosteviol can relieve concanavalin A-induced hepatocyte swelling and necrosis in mice. Isosteviol can inhibit elevation of serum glutamic-pyruvic transaminase, glutamic-oxalacetic transaminase and lactate dehydrogenase; reduce the levels of serum inflammatory factors interleukin 6(IL-6), tumor necrosis factor alpha (TNF-alpha) and interleukin 1 beta (IL-1 beta). Reducing the expression of IL-6, TNF-alpha, IL-1 beta, macrophage inflammatory protein 1 alpha, intercellular adhesion molecule 1 and C-X-C motif chemokine 10 in the liver tissue of the mice. These effects indicate that isosteviol can be used for the treatment of autoimmune hepatitis, and has a prospect of drug development.